Story thread · 12 reports / 5 sources
Arcturus targets Q4 2026 Phase III decision for ARCT-032 as it regains global KOSTAIVE rights
seekingalpha.com · 4d
First report: Knight Therapeutics Reports Second Quarter 2026 Results — thestar.com, 5d
The coverage
- QuidelOrtho Q2 Earnings Call Highlights
finance.yahoo.com · 4d
- QuidelOrtho: Q2 Earnings Snapshot
wtop.com · 5d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.